MindBio Therapeutics receives approval for LSD-based drug clinical trials to treat PMS/PMDD.

MindBio Therapeutics has received approval for clinical trials using its LSD-based drug, MB22001, to treat women's health, specifically premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The drug is designed for self-administration during specific menstrual phases and has shown mood-elevating and antidepressant effects in previous trials. The trials will be the first to study psychedelic response across the menstrual cycle and could contribute to new PMS/PMDD treatments.